• SPX
  • 6090.27
  • 0.25 %
  • 15.1602
  • DJI
  • 44642.52
  • -0.28 %
  • -123.1914
  • N225
  • 39091.17
  • -0.77 %
  • -304.4297
  • FTSE
  • 8308.61
  • -0.49 %
  • -40.7695
  • IXIC
  • 19859.773
  • 0.81 %
  • 159.0508
argenx SE (ARGX) Stock Price, News & Analysis

argenx SE (ARGX) Stock Price, News & Analysis

Currency in USD Disclaimer

$623.67

-$2.45

(-0.39%)

Day's range
$619.75
Day's range
$628.6
50-day range
$514.92
Day's range
$630
  • Country: NL
  • ISIN: US04016X1019
52 wk range
$327.73
Day's range
$630
  • CEO: Mr. Timothy Van Hauwermeiren EMBA, M.Sc.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 42.76
  • Piotroski Score 2.00
  • Grade Outperform
  • Symbol (ARGX)
  • Company argenx SE
  • Price $623.67
  • Changes Percentage (-0.39%)
  • Change -$2.45
  • Day Low $619.75
  • Day High $628.60
  • Year High $630.00

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 02/27/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $540.00
  • High Stock Price Target $715.00
  • Low Stock Price Target $500.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$5.69
  • Trailing P/E Ratio -66.05
  • Forward P/E Ratio -66.05
  • P/E Growth -66.05
  • Net Income $-295,053,000

Income Statement

Quarterly

Annual

Latest News of ARGX

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

  • Why Is Argenx SE (ARGX) Among the Best High Growth Healthcare Stocks to Invest In Now?

    The article discusses the growth potential of healthcare stocks amid increasing global healthcare spending trends. It highlights the importance of investing in sectors like pharmaceuticals, medical eq...

    By Yahoo! Finance | 4 days ago
  • Here's Why argenx SE (ARGX) Rose 9% in Q2

    TimesSquare Capital Management shared its U.S. Mid Cap Growth Strategy's Q2 investor letter, emphasizing top-performing U.S. stocks. Argenx SE (NASDAQ: ARGX) stood out in the biotech sector, with a 2....

    By Yahoo! Finance | 2 months ago
  • What Made argenx SE (ARGX) Rise in Q2?

    Artisan Partners' Q2 2024 investor letter discussed the performance of the Artisan Mid Cap Fund, noting negative returns and underperformance compared to the index. The fund highlighted Argenx SE (NAS...

    By Yahoo! Finance | 4 months ago
Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

argenx SE Frequently Asked Questions

  • What were the earnings of ARGX in the last quarter?

    In the last quarter argenx SE earnings were on Thursday, October, 31st. The argenx SE maker reported $1.39 EPS for the quarter, beating analysts' consensus estimates of $0.10 by $1.29.

  • What is the argenx SE stock price today?

    Today's price of argenx SE is $623.67 — it has decreased by -0.39% in the past 24 hours. Watch argenx SE stock price performance more closely on the chart.

  • Does argenx SE release reports?

    Yes, you can track argenx SE's financials in yearly and quarterly reports directly on Stocks.News.

  • What is the argenx SE stock forecast?

    Watch the argenx SE chart and read a more detailed argenx SE stock forecast to see what analysts suggest you do with its shares.

  • What is argenx SE stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by argenx SE stock ticker.

  • How to buy argenx SE stocks?

    Like other stocks, ARGX shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is argenx SE's EBITDA?

    argenx SE measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in argenx SE’s financial statements.

  • What is the argenx SE's net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -0.2406011175, which equates to approximately -24.06%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in argenx SE stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including argenx SE's financials relevant news, and technical analysis. argenx SE's technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for argenx SE stock currently indicates a “sell” signal. For more insights, review argenx SE’s technical analysis.

  • A revenue figure for argenx SE for its last quarter?

    argenx SE published it's last quarterly revenues at $573.24 M.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.